University of Lyon 1 Claude-Bernard, Villeurbanne, France; Pediatric Pulmonology and Allergology Department, Pediatric Cystic Fibrosis Center, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.
Pediatric Pulmonology and Allergology Department, Pediatric Cystic Fibrosis Center, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.
Ann Allergy Asthma Immunol. 2022 Apr;128(4):432-438. doi: 10.1016/j.anai.2022.01.002. Epub 2022 Jan 8.
Hazelnut oral immunotherapy (H-OIT), a promising alternative to hazelnut-free diet for patients with hazelnut allergy, has not been extensively studied.
To investigate the effectiveness of H-OIT for children with hazelnut allergy.
Retrospective medical record review of children treated by H-OIT in the University Hospital of Lyon (France) was reported. Clinical and laboratory data were collected, and the satisfaction of the children treated by H-OIT was evaluated using a questionnaire.
A total of 70 patients treated by H-OIT for an immunoglobulin E-mediated hazelnut allergy (94.3%) or an immunoglobulin E sensitization to hazelnut (5.7%) were included. Among these, 22.9% entered the maintenance phase at 1-year consultation and 60.0% entered the maintenance phase during the study period. At home, 57.1% of the patients experienced at least 1 adverse effect and 2.9% experienced severe systemic allergic reactions. Among the 212 oral food challenges conducted at hospital, 3.3% led to severe systemic reactions and epinephrine was used 4 times. A total of 21.4% of children discontinued treatment; aversion to hazelnut was the main reason. There were 42 children aged 8 years or more and their parents who answered the questionnaire. H-OIT was considered a strain for children but effective and was recommended to other children with allergy.
H-OIT seemed to be effective and well accepted by children. This is counterbalanced by a high rate of H-OIT discontinuation, mainly owing to aversion to hazelnut, and an important rate of adverse reactions, which are however mostly mild.
ClinicalTrials.gov Identifier: NCT04841850.
榛子口服免疫疗法（H-OIT）是一种有前途的榛子过敏患者替代无榛子饮食的方法，但尚未广泛研究。
研究 H-OIT 治疗榛子过敏儿童的有效性。
报告了法国里昂大学医院（University Hospital of Lyon）对接受 H-OIT 治疗的儿童进行的回顾性病历审查。收集了临床和实验室数据，并使用问卷评估了接受 H-OIT 治疗的儿童的满意度。
共纳入 70 例接受 H-OIT 治疗的 IgE 介导的榛子过敏（94.3%）或 IgE 对榛子致敏（5.7%）的患者。其中，22.9%在 1 年就诊时进入维持阶段，60.0%在研究期间进入维持阶段。在家中，57.1%的患者至少出现 1 次不良反应，2.9%出现严重全身性过敏反应。在医院进行的 212 次口服食物挑战中，有 3.3%导致严重全身性反应，4 次使用肾上腺素。共有 21.4%的儿童停止治疗；对榛子的厌恶是主要原因。有 42 名年龄在 8 岁或以上的儿童及其家长回答了问卷。H-OIT 被认为对儿童有一定的压力，但有效，并被推荐给其他过敏的儿童。
H-OIT 似乎有效且被儿童接受。但 H-OIT 的终止率较高，主要是由于对榛子的厌恶，以及不良反应的发生率较高，但大多数是轻微的。
ClinicalTrials.gov 标识符：NCT04841850。
